Leuprorelin
Leuprorelin (Camcevi, Accord Healthcare S.L.U.) has 2 EU-approved indications in 1 tumour type.
| Biomarker requirement | Regimen | Setting | Conditions |
|---|---|---|---|
| Prostate cancer2 | |||
None | + radiotherapy | Any line | High-risk localised or locally advanced; hormone dependent |
None | Monotherapy | Any line advanced | Hormone dependent |
Full text of section 4.1 (therapeutic indications)
CAMCEVI is indicated for the treatment of hormone dependent advanced prostate cancer and for the treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy.
Label history
7 changes to the Camcevi label since 2024, none of them to the indications. Newest first, in the words of EMA's record of each procedure.
Changes